ArticleCureus2025
Outcomes of Radical Radiotherapy in Prostate Cancer Patients Over 80 Years of Age.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Despite advances in surgery, radiotherapy, and systemic therapies, treatment selection and sequencing remain major challenges in optimizing outcomes for patients with prostate cancer. Men aged 50-69 years with screen-detected disease often achieve favorable outcomes across various treatment strategies, whether managed with active monitoring, prostatectomy, or radical radiotherapy. However, limited information is available on outcomes in older patients. This study retrospectively evaluates survival outcomes in older patients treated with radical radiotherapy at a tertiary UK cancer center. Methods At Clatterbridge Cancer Centre NHS Foundation Trust, the electronic health records system was used to identify patients aged 80 years or older who received radical radiotherapy over a five-year period, with at least five years of follow-up. Demographic data collected included disease risk profile and comorbidities. Biochemical recurrence-free survival (BFS), metastasis-free survival (MFS), hormone-free survival (HFS), and overall survival (OS) were analyzed. Results Between January 2013 and December 2017, 82 patients were treated and analyzed. The median age was 81 years, and most patients had a performance status of 0 or 1 with minimal significant comorbidities. Prostate cancer was classified as high or very high risk (National Comprehensive Cancer Network) in 88% of patients. Five-year BFS, MFS, HFS, and OS were 77%, 88%, 86%, and 77%, respectively. Despite receiving radical radiotherapy, 21% of deaths were attributable to prostate cancer. Conclusions Prostate cancer patients aged 80 years or older treated with radical radiotherapy can achieve favorable BFS and HFS despite high-risk disease. These outcomes are clinically meaningful, as untreated disease may lead to worsening symptoms and the future need for lifelong hormone therapy with its associated toxicities. Nonetheless, a substantial proportion of patients will die from the disease despite receiving radical radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.